
Parth Patel
Oct 2, 2025
15 min
The Great Reshuffling: Which Stocks Will Dominate the Next Decade?
JPMorgan's "Navigating the Future" report reveals three seismic shifts poised to separate winners from losers by 2035
The pace of technological change has never been faster—and it will never be this slow again. JPMorgan's Corporate Finance Advisory team just released their strategic outlook for the next decade, and the implications for investors are staggering. Three converging forces—artificial intelligence breakthroughs, energy market transformation, and healthcare longevity advances—will create the widest performance gap between winning and losing stocks in modern market history.
Here's what the data reveals about which companies will thrive and which face obsolescence.
The AI Revolution: Knowledge Workers First, Manufacturing Maybe Never
ChatGPT reached 100 million users in 2 months. Netflix took 10 years. That adoption velocity tells you everything about AI's disruptive potential.
JPMorgan's six-factor AI leverage model assessed every S&P 500 sector on efficiency opportunity, innovation potential, and adaptability. The verdict: services sectors dominate, manufacturing lags—a complete reversal from previous technological revolutions.
AI Winners: The Knowledge Economy Elite
Pharmaceuticals & Biotechnology
Stocks to watch: Eli Lilly
LLY, Novo NordiskNVO, Vertex PharmaceuticalsVRTX, ModernaMRNACatalyst: AI slashes drug development timelines by 30-50%, with trials using machine learning showing 25-30% faster completion rates
Risk: $880 million average drug development cost remains barrier despite AI efficiencies
Software & Services
Stocks to watch: Microsoft
MSFT, AlphabetGOOGL, SalesforceCRM, ServiceNowNOW, PalantirPLTRCatalyst: Low revenue-per-employee models gain massive leverage; coding assistants increase developer productivity 25-30%
Risk: Talent wars intensify; smaller players face commoditization
Financial Services
Stocks to watch: JPMorgan Chase
JPM, VisaV, MastercardMA, S&P GlobalSPGI, BlackRockBLKCatalyst: Process automation drives margin expansion; fraud detection accuracy improvements exceed 90%
Risk: Regulatory complexity; cybersecurity vulnerabilities scale with AI adoption
Semiconductors
Stocks to watch: NVIDIA
NVDA, Taiwan SemiconductorTSM, ASMLASML, BroadcomAVGO, AMDAMDCatalyst: Hyperscaler capex growing 32% CAGR since 2020; data center demand structural not cyclical
Risk: $420 billion in committed AI capex through 2026 creates oversupply risk if adoption slows
AI Losers: Physical World Constraints
Consumer Staples & Food
Vulnerable names: Kraft Heinz
KHC, Campbell SoupCPB, ConagraCAGProblem: Low gross margins per employee; limited R&D leverage; physical distribution bottlenecks
Reality check: AI can't fundamentally change the economics of moving tomato soup from factory to shelf
Automobiles
Mixed outlook: Traditional OEMs lag (Ford
F, GMGM) while EV-native companies (TeslaTSLA) maintain advantageProblem: Capital-intensive manufacturing; autonomous vehicle timeline remains 5-10 years out despite hype
Exception: Auto suppliers with software focus (Aptiv
APTV) positioned better than vehicle assemblers
The Energy Paradox: Short-Term Pain, Long-Term Abundance
AI's voracious power appetite creates a fascinating market dynamic: near-term price spikes followed by structural deflation as investment floods into generation capacity.
The Near-Term Crunch (2025-2027)
PJM capacity auction prices jumped from $2.2 billion to $16.1 billion—a 632% increase—as data center demand outpaced grid expansion. Hyperscaler capex projections keep getting revised upward: Microsoft alone announced then delayed $80 billion in data center buildouts.
Vulnerable to Energy Spikes:
Transportation: United Airlines
UAL, FedExFDX, Norfolk SouthernNSC—fuel represents 50% of operating costsMaterials: Alcoa
AA, NucorNUE, MosaicMOS—energy-intensive production loses competitivenessIndustrial Manufacturing: Caterpillar
CAT, DeereDEface margin compression
The Long-Term Flip (2030-2050)
North American utility capex rising 18% annually through 2029, with 94 GW of new capacity planned (60% nuclear, 28% gas). Renewable electricity costs fell 88% for solar since 2009, with fusion commercialization targeting early 2030s.
Energy Deflation Beneficiaries:
Stock | Ticker | Catalyst | Timeframe |
|---|---|---|---|
Transportation | Union Pacific (UNP), CSX (CSX) | Fuel costs decline 60-80%; margins expand 500-1000 bps | 2030+ |
Data Centers | Equinix (EQIX), Digital Realty (DLR) | Power constraints removed; capacity doubles | 2028-2035 |
Semiconductors | Intel (INTC), Micron (MU) | Fab operating costs fall 40-60% | 2030+ |
Materials | Freeport-McMoran (FCX), Steel Dynamics (STLD) | Energy-intensive production becomes advantage | 2032+ |
Energy Transition Winners:
Utilities executing capex: NextEra Energy
NEE, Duke EnergyDUK, Southern CompanySOGrid infrastructure: Quanta Services
PWR, MasTecMTZRenewable developers: First Solar
FSLR, EnphaseENPHNuclear: Constellation Energy
CEG, VistraVSTBattery storage: Tesla Energy, Fluence (private)
Energy Transition Losers:
Fossil fuel producers: ExxonMobil
XOM, ChevronCVXface structural demand declineCoal exposure: Peabody Energy
BTU, Arch ResourcesARCHStranded asset risk: Pipeline operators with 30-year contracted cash flows (Kinder Morgan
KMI, Williams CompaniesWMB)
The Longevity Boom: Healthcare Transforms Retirement Economics
GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) reached 3rd-most prescribed medication status in history. Pipeline approvals through 2028 expand indications to heart failure, Alzheimer's, chronic kidney disease, and 5+ additional conditions.
Life expectancy gains of 2 years create $2.4-$16.4 trillion in economic value through changed consumption patterns—but also generate $3.2 trillion in Medicare/Social Security costs and $148 billion in unfunded corporate pension liabilities for S&P 500 companies.
Healthcare Longevity Winners
Pharmaceuticals (GLP-1 Leaders)
Company | Ticker | Drug Franchise | 2024-2028 Opportunity |
|---|---|---|---|
Eli Lilly | LLY | Mounjaro/Zepbound (tirzepatide) | Cardiovascular, MASH, CKD approvals expand TAM 300% |
Novo Nordisk | NVO | Ozempic/Wegovy (semaglutide) | Alzheimer's, diabetic retinopathy trials de-risk pipeline |
Amgen | AMGN | MariTide (maridebart café) | 2028 launch targets GLP-1 adherence problem |
Healthcare Equipment & Diagnostics
AI-powered diagnostics: Intuitive Surgical
ISRG, DexcomDXCM, Abbott LabsABTAging population tailwinds: Medtronic
MDT, StrykerSYK, Boston ScientificBSXRemote monitoring: Teladoc
TDOC—turnaround candidate if execution improves
Gene Therapy & Longevity
CRISPR leaders: CRISPR Therapeutics
CRSP, Editas MedicineEDIT, Intellia TherapeuticsNTLALongevity biotech: Unity Biotechnology
UBX, GeronGERN—high risk/reward
Senior Housing & Services
REITs: Welltower
WELL, VentasVTR, Healthpeak PropertiesPEAKServices: Brookdale Senior Living
BKD—turnaround story if occupancy improves
Longevity-Driven Headwinds
Pension Liability Explosion
Heavy exposure: General Electric
GE, Lockheed MartinLMT, RaytheonRTX, BoeingBAProblem: 3-year life expectancy increase = 10% jump in pension obligations
De-risking leaders: Prudential
PRU, Athene (merged with ApolloAPO) facilitate pension risk transfers
Consumer Staples Disruption
Processed food vulnerable: Mondelez
MDLZ, General MillsGIS, Kellogg'sKReality check: Healthier aging populations consume less packaged/processed foods; GLP-1 users reduce calorie intake 20-30%
Life Insurance Repricing
Actuarial model disruption: MetLife
MET, PrudentialPRU, Lincoln NationalLNCRequired action: Premium restructuring as mortality assumptions shift 15-20%
Cross-Scenario Synthesis: The Multi-Threat Winners
The truly exceptional opportunities sit at the intersection of all three scenarios:
Triple-Leverage Stocks
1. Eli Lilly (LLY)
AI advantage: Drug discovery AI reduces R&D costs 30-40%
Energy benefit: Minimal energy intensity; knowledge-based business model
Healthcare catalyst: GLP-1 franchise expanding into 8+ conditions; $50+ billion revenue potential by 2030
2. NVIDIA (NVDA)
AI advantage: 80%+ market share in AI accelerators; software moat strengthens
Energy benefit: Data center expansion benefits from cheap power post-2030
Healthcare crossover: Medical imaging AI, drug discovery partnerships
3. Microsoft (MSFT)
AI advantage: Azure AI services; Copilot productivity gains; OpenAI partnership
Energy benefit: Demand response programs manage data center costs; long-term power deflation
Healthcare exposure: Nuance Communications acquisition positions for medical AI
4. UnitedHealth Group (UNH)
AI advantage: Claims processing automation; fraud detection; care management optimization
Energy benefit: Services business with minimal energy intensity
Healthcare catalyst: Aging population drives membership growth; Optum platform scales
5. Intuitive Surgical (ISRG)
AI advantage: Robotic surgery platforms integrate machine learning for outcome improvements
Energy benefit: Minimal energy footprint; knowledge-intensive business
Healthcare catalyst: Aging population requires more surgical interventions; global expansion
The Contrarian Plays: Underestimated Recovery Stories
Utilities (Selective)
The bet: Near-term capex surge ($250B+ annually) positions grid operators for long-term dominance
Winners: NextEra Energy
NEE, Duke EnergyDUK—execution on buildoutLosers: Utilities delaying investment face obsolescence
Traditional Semiconductors (Intel)
The thesis: Energy deflation makes U.S. fabs competitive again; CHIPS Act subsidies de-risk investment
Risk: Execution turnaround required; competitive position deteriorated significantly
Banks (Regional)
The setup: AI operational efficiency + energy-light business model + wealth management for longer-living clients
Picks: M&T Bank
MTB, Fifth ThirdFITB—technology investment leadersAvoid: Banks with heavy commercial real estate exposure to obsolete office/retail
The Death Watch: Terminal Decline Candidates
Fossil Fuel Exposure
Structural headwinds: Demand peak by 2030; stranded asset risks; ESG capital flight
At risk: Coal producers (
BTU,ARCH), pure-play E&Ps, pipeline operators with 30-year contracted life
Brick-and-Mortar Retail
Triple threat: AI-powered e-commerce + high energy costs (physical locations) + aging consumer digital shift
Vulnerable: Department stores (Macy's
M, NordstromJWN), mall-based specialty retail
Legacy Manufacturing
Structural disadvantages: Limited AI integration + energy-intensive + aging workforce retirement
At risk: Auto suppliers without software pivot, commodity chemical producers
Commercial Real Estate (Office/Retail)
Secular decline: Remote work permanence + retail e-commerce shift + demographic patterns
Avoid: Office REITs (
BXP,VNO), mall REITs (SPGselective)
Implementation Framework: Building a Future-Proof Portfolio
Core Holdings (40-50%)
High-conviction multi-scenario winners:
Eli Lilly
LLY: 8-10%Microsoft
MSFT: 8-10%NVIDIA
NVDA: 6-8%UnitedHealth
UNH: 6-8%JPMorgan Chase
JPM: 6-8%NextEra Energy
NEE: 4-6%
Thematic Exposure (30-40%)
AI Infrastructure (15-20%):
Semiconductors: ASML, Broadcom, AMD
Cloud: Alphabet, Amazon
Software: Palantir, ServiceNow
Healthcare Innovation (10-15%):
Novo Nordisk, Intuitive Surgical, Dexcom
CRISPR/gene therapy: 2-3% allocation to high-risk/reward names
Energy Transition (5-10%):
Utilities: Duke, Constellation
Grid infrastructure: Quanta Services
Nuclear: Cameco
CCJ
Contrarian/Value (10-20%)
Turnaround candidates with scenario optionality:
Select regional banks (5-7%)
Utility laggards with new management (3-5%)
Distressed healthcare services (2-3%)
Hedges (5-10%)
Portfolio insurance against scenario failures:
Energy MLPs for near-term spike protection
Treasury bonds for recession/deflation
Gold for geopolitical/inflation tail risks
Critical Reality Checks: What Could Go Wrong
AI Scenario Risks
Regulatory intervention (EU AI Act serves as template for U.S. restrictions)
Compute bottlenecks persist longer than expected (chip shortage 2.0)
Cybersecurity breaches undermine trust; adoption stalls
AGI timeline slips 5-10 years; expectations reset violently
Energy Scenario Risks
Grid infrastructure buildout delayed by permitting/labor shortages
China weaponizes battery materials monopoly (95% of graphite supply)
Climate events disrupt generation faster than capacity additions
Fusion commercialization fails; nuclear renaissance stalls
Healthcare Scenario Risks
GLP-1 adherence crisis worsens (already 50% discontinuation within 12 months)
Drug pricing regulation caps profitability; R&D investment declines
Healthcare cost inflation exceeds longevity economic benefits
Medicare/Social Security become politically unsustainable; benefits cut
The 80-Year Lesson: Humility in Forecasting
JPMorgan opens the report with a 1946 Atlantic article that correctly predicted baby boom impacts on schools, housing, and retirement systems—but completely missed industrialization, globalization, and the technology revolution.
The takeaway: directional accuracy matters more than precision. We know AI, energy, and healthcare will transform the economy. Specific timelines and magnitudes remain unknowable.
The companies that thrive won't be those with perfect predictions. They'll be those with adaptive capacity—balance sheets that weather near-term volatility, management teams that pivot as scenarios unfold, and business models with optionality across multiple futures.
Bottom Line: The Great Divergence
The performance gap between winners and losers will exceed any prior technological transition. Knowledge-intensive businesses with AI leverage, energy efficiency, and demographic tailwinds compound advantages. Capital-intensive businesses with physical constraints, energy intensity, and pension liabilities face terminal decline.
The S&P 500's equal-weighted return will dramatically underperform its cap-weighted return. Passive indexing faces a decade of reckoning. Active management resurges for those who correctly position for these three transformative scenarios.
The future belongs to companies that treat 2025 as the beginning of a new economic era—not the continuation of the last one.
Disclosure: This analysis is for informational purposes only and does not constitute investment advice. All investments carry risk, including loss of principal. Conduct your own due diligence and consult with financial advisors before making investment decisions. Stock mentions do not constitute recommendations to buy or sell securities.
This content is based on JPMorgan's "Navigating the Future" report (September 2025) and publicly available market data. Past performance does not guarantee future results. Market conditions, regulations, and company circumstances can change rapidly.

